These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27169431)

  • 1. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).
    Strand V; Mease P; Gossec L; Elkayam O; van den Bosch F; Zuazo J; Pricop L; Mpofu S;
    Ann Rheum Dis; 2017 Jan; 76(1):203-207. PubMed ID: 27169431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
    Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
    N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB; Mease PJ; Schett G; Kirkham B; Strand V; Williams N; Fox T; Pricop L; Jugl SM; Gandhi KK;
    Arthritis Res Ther; 2018 Jun; 20(1):113. PubMed ID: 29880010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.
    Kavanaugh A; Mease PJ; Reimold AM; Tahir H; Rech J; Hall S; Geusens P; Wang Z; Pricop L; Mpofu S;
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):347-355. PubMed ID: 27696786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
    Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
    Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
    McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
    Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
    Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
    Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
    Coates LC; Mease PJ; Gossec L; Kirkham B; Sherif B; Gaillez C; Mpofu S; Jugl SM; Karyekar C; Gandhi KK
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1529-1535. PubMed ID: 29409133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial.
    Strand V; Kaeley GS; Bergman MJ; Gladman DD; Coates LC; Sherif B; Hur P; Parikh B; Gilloteau I; Mease PJ
    Lancet Rheumatol; 2022 Mar; 4(3):e208-e219. PubMed ID: 38288937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
    Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
    J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial.
    Strand V; Alemao E; Lehman T; Johnsen A; Banerjee S; Ahmad HA; Mease PJ
    Arthritis Res Ther; 2018 Dec; 20(1):269. PubMed ID: 30522501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
    Nash P; Mease PJ; McInnes IB; Rahman P; Ritchlin CT; Blanco R; Dokoupilova E; Andersson M; Kajekar R; Mpofu S; Pricop L;
    Arthritis Res Ther; 2018 Mar; 20(1):47. PubMed ID: 29544534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.
    van der Heijde D; Landewé RB; Mease PJ; McInnes IB; Conaghan PG; Pricop L; Ligozio G; Richards HB; Mpofu S
    Arthritis Rheumatol; 2016 Aug; 68(8):1914-21. PubMed ID: 27014997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
    Baraliakos X; Gossec L; Pournara E; Jeka S; Mera-Varela A; D'Angelo S; Schulz B; Rissler M; Nagar K; Perella C; Coates LC
    Ann Rheum Dis; 2021 May; 80(5):582-590. PubMed ID: 33334727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
    Tlustochowicz W; Rahman P; Seriolo B; Krammer G; Porter B; Widmer A; Richards HB
    J Rheumatol; 2016 Mar; 43(3):495-503. PubMed ID: 26834211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.